Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Surgical Sealants, Inc. Hoping To Debut SurgiSeal Vascular Sealant In 2000

This article was originally published in The Gray Sheet

Executive Summary

Development stage Surgical Sealants, Inc. is currently conducting clinical trials of its collagen-based SurgiSeal vascular sealant and expects to submit a 510(k) to FDA by year-end.

You may also be interested in...



In Brief: Bio-Vascular

Bio-Vascular: Expects accelerated European sales of its Peri-Strips Dry bovine pericardium-based staple line reinforcements in late 1997, when the company is scheduled to complete multi-center trials evaluating use of the products in lung volume reduction procedures performed on patients suffering from late-stage emphysema. The company commenced U.S. sales of the product, which replaces an earlier version of the Peri-Strips device, in mid-July following FDA clearance in early May...

FUSION MEDICAL TECHNOLOGIES RAPISEAL 510(k) FILED IN APRIL, FIRM SAYS IN PROSPECTUS; 96% EFFECTIVENESS RATE IN LUNG RESECTION PATIENTS SHOWN IN CLINICALS

Fusion Medical Technologies' RapiSeal collagen-based biodegradable patch successfully treated 96% of air leaks in a study of cancer patients who were undergoing lung resection surgery, the Mountain View, California-based firm says in a preliminary prospectus for its initial public offering.

Celltrion Makes Progress On Coronavirus Treatment

Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

UsernamePublicRestriction

Register

MT012211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel